Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemircopan (ALXN2050) in Generalized Myasthenia Gravis
NCT05218096Phase 2Terminated
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of vemircopan in myasthenia gravis (MG) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Percentage Of Participants With a Myasthenia Gravis Activities of Daily Living Total Score Reduction Of ≥ 2 Points In Any 4 Consecutive Weeks at 8 weeks. Started Apr 2022; status: terminated.
02
Drugs
vemircopan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05218096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218096.